Skip to search formSkip to main contentSkip to account menu

ficlatuzumab

Known as: Anti-HGF Monoclonal Antibody SCH900105 
A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. Ficlatuzumab binds to… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

AV-299

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.
693Background: Paired-related homeodomain transcription factor 1 (Prrx1) isoforms are involved in pancreatic development… 
2017
2017
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
6038Background: Cetuximab, an anti-EGFR mAb, is approved for R/M HNSCC but only a minority benefits. Activation of cMet, the… 
2015
2015
Abstract A55: Tumor-associated fibroblasts: A new target for cancer treatment
Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with a 50% rate of local failure with current standard… 
2014
2014
205PEFFICACY ANALYSIS OF GEFITINIB +/- FICLATUZUMAB IN SERUM PROTEOMIC BASED SUBGROUPS OF PATIENTS WITH PREVIOUSLY UNTREATED LUNG ADENOCARCINOMA.
ABSTRACT Aim: Ficlatuzumab (F), a humanized anti-hepatocyte growth factor (HGF) IgG1 mAb, inhibits c-MET receptor activation by… 
2013
2013
Cancer Therapy : Preclinical Preclinical Ef fi cacy of the Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab in a Mouse Brain Orthotopic Glioma Model Evaluated by Bioluminescence , PET , and MRI
Purpose: Ficlatuzumab is a novel therapeutic agent targeting the hepatocyte growth factor (HGF)/c-MET pathway. We summarize… 
Review
2013
Review
2013
Signaling control by epidermal growth factor receptor and MET: rationale for cotargeting strategies in lung cancer.
In a report accompanying our article, Spigel et al present their findings on combining erlotinib, an epidermal growth factor… 
2013
2013
Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib.
2012
2012
TM-03. EFFECTS OF COMBINATION OF FICLATUZUMAB WITH ANTI-VEGF INHIBITORS ON GLIOBLASTOMA XENOGRAFTS
Glioblastoma development should be subdivided in three phases, one prehypoxic and two post-hypoxic phases. The pre-hypoxic phase… 
2012
2012
302 Antitumor Activity of Ficlatuzumab in Combination with Cetuximab On Squamous Cell Carcinomas of the Head and Neck
2011
2011
Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
7571 Background: Ficlatuzumab is a humanized anti-HGF IgG1 MAb that inhibits activation of the c-Met receptor by neutralizing its… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)